CA2449488C - Compositions and methods for treating hyperimmune response in the eye - Google Patents

Compositions and methods for treating hyperimmune response in the eye Download PDF

Info

Publication number
CA2449488C
CA2449488C CA2449488A CA2449488A CA2449488C CA 2449488 C CA2449488 C CA 2449488C CA 2449488 A CA2449488 A CA 2449488A CA 2449488 A CA2449488 A CA 2449488A CA 2449488 C CA2449488 C CA 2449488C
Authority
CA
Canada
Prior art keywords
antibodies
eye
antibody
gamma
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2449488A
Other languages
English (en)
French (fr)
Other versions
CA2449488A1 (en
Inventor
Simon Skurkovich
Boris Skurkovich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Biotherapy Concepts Inc
Original Assignee
Advanced Biotherapy Concepts Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Biotherapy Concepts Inc filed Critical Advanced Biotherapy Concepts Inc
Publication of CA2449488A1 publication Critical patent/CA2449488A1/en
Application granted granted Critical
Publication of CA2449488C publication Critical patent/CA2449488C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA2449488A 2001-06-05 2002-06-04 Compositions and methods for treating hyperimmune response in the eye Expired - Fee Related CA2449488C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29589501P 2001-06-05 2001-06-05
US60/295,895 2001-06-05
US09/894,287 US6534059B2 (en) 2001-06-05 2001-06-28 Compositions and methods for treating hyperimmune response in the eye
US09/894,287 2001-06-28
PCT/US2002/017677 WO2002098460A1 (en) 2001-06-05 2002-06-04 Compositions and methods for treating hyperimmune response in the eye

Publications (2)

Publication Number Publication Date
CA2449488A1 CA2449488A1 (en) 2002-12-12
CA2449488C true CA2449488C (en) 2010-02-09

Family

ID=26969391

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2449488A Expired - Fee Related CA2449488C (en) 2001-06-05 2002-06-04 Compositions and methods for treating hyperimmune response in the eye

Country Status (8)

Country Link
US (2) US6534059B2 (https=)
EP (1) EP1401496B1 (https=)
JP (1) JP2004532885A (https=)
AT (1) ATE343398T1 (https=)
AU (1) AU2002318175B2 (https=)
CA (1) CA2449488C (https=)
DE (1) DE60215649D1 (https=)
WO (1) WO2002098460A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6709655B2 (en) * 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
US6861056B2 (en) * 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US6534059B2 (en) * 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US6712976B2 (en) * 2001-09-13 2004-03-30 Abtech Industries, Inc. Dual-action decontamination system
US7335759B2 (en) 2002-12-02 2008-02-26 Universidad Nacional Autónoma de Méxica (UNAM) Recombinant immunogens for the generation of antivenoms to the venom of scorpions of the genus Centruroides
EP1651266B1 (en) * 2003-07-25 2010-03-03 Laboratorios Silanes, S.A. de C.V. Administration of anti-tnf-alpha f(ab')2 antibody fragments
PT1848744E (pt) 2005-01-27 2012-04-24 Novimmune Sa Anticorpos anti-interferão gama e os seus processos de utilização
US20100003264A1 (en) * 2005-03-24 2010-01-07 Washington University Reduction of Ophthalmalogic Neovascularization
US7381802B2 (en) * 2005-04-15 2008-06-03 Universidad Nacional Autónoma De México (UNAM) Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom
CA2654565A1 (en) * 2006-06-12 2007-12-21 Therakine Limited Topical treatment for diseases of eye surface
EP2326342B1 (en) 2008-08-15 2021-10-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using interferon gamma to absorb fluid from the subretinal space
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
CN121588213A (zh) 2015-05-07 2026-03-03 瑞典孤儿比奥维特鲁姆股份公司 用于诊断和治疗cxcl9和其它生物标志物水平升高的患者的病症

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
UA41863C2 (uk) 1985-10-25 2001-10-15 Займодженетікс Інк. Спосіб одержання гетерологічного поліпептиду в еукаріотичних мікроорганізмах
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
DE69229275T2 (de) * 1991-10-04 1999-12-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
DE19535073C1 (de) * 1995-09-21 1997-02-20 Roland Dr Grosmann Verfahren zur künstlichen Inkubation von Hühnereiern
US6861056B2 (en) * 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US6534059B2 (en) * 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye

Also Published As

Publication number Publication date
EP1401496A4 (en) 2005-08-31
US6534059B2 (en) 2003-03-18
US20030224005A1 (en) 2003-12-04
AU2002318175B2 (en) 2006-01-05
WO2002098460A1 (en) 2002-12-12
HK1063601A1 (en) 2005-01-07
ATE343398T1 (de) 2006-11-15
DE60215649D1 (de) 2006-12-07
CA2449488A1 (en) 2002-12-12
EP1401496A1 (en) 2004-03-31
US20020182212A1 (en) 2002-12-05
EP1401496B1 (en) 2006-10-25
JP2004532885A (ja) 2004-10-28
US7232568B2 (en) 2007-06-19

Similar Documents

Publication Publication Date Title
CA2449488C (en) Compositions and methods for treating hyperimmune response in the eye
CA2637917C (en) Therapeutic agents for diseases involving choroidal neovascularization
WO2009014263A1 (ja) インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
AU2002318175A1 (en) Compositions and methods for treating hyperimmune response in the eye
EP1161954A1 (en) Treatment of T cell mediated autoimmune disorders
EP1004312A1 (en) Method for treating multiple sclerosis
CZ297083B6 (cs) Cinidlo pro prevenci a lécbu zánetlivého onemocnení streva obsahující aktivní slozku antagonistu IL-6
US20040086508A1 (en) Treatment of organ transplant rejection
US6861056B2 (en) Compositions and methods for treating hyperimmune response in the eye
DE69736244T2 (de) Lösliche lymphotoxin-beta rezeptoren, anti-lymphotoxin-antikörper und anti-lymphotoxin ligand antikörper als therapeutische wirkstoffe zur behandlung von immunologischen krankheiten
HU211059B (en) Method for producing pharmaceutical compositions usable for reducing immunglobulin e responses, containing human il-4 antibodies
US20040062768A1 (en) Compositions and methods for treating hyperimmune response in the eye
JPH08506325A (ja) サイトメガロウイルスに対するヒトモノクローナル抗体
US6333035B1 (en) Medicinal composition containing gp34 binding-inhibitor as the active ingredient
HK1063601B (en) Compositions and methods for treating hyperimmune response in the eye
US20050152902A1 (en) Treatment of diabetic retinopathy
CN114901313A (zh) 急性期的视神经脊髓炎的预防或治疗剂
US7462454B2 (en) Treatment of herpes
US20040247589A1 (en) Anti-tumor activity from reptile serum
JP2528549B2 (ja) ヒトｉｌ―２レセプタ―重鎖に結合する新規モノクロ―ナル抗体
HK1062408B (en) Remedies for infant chronic arthritis-relating diseases
HK1062408A1 (zh) 小儿慢性关节炎相关疾病治疗剂
HK1028554A (en) Method for treating multiple sclerosis

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed